Dr. Rugo Discusses MONARCH I in HR+ HER2- Breast Cancer

Video

In Partnership With:

Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.

Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.

The final overall analysis of the phase II study of abemaciclib, a CDK4/6 inhibitor, showed an overall survival of about 22 months.

This trial suggests that abemaciclib has significant single-agent activity. Additionally, this agent may improve progression-free survival when combined with hormone therapy such as fulvestrant (Faslodex), says Rugo.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Minesh Mehta, MD
Ruben Olivares, MD